BR112014014131A2 - formulações de pastilha e cápsula com taxas melhoradas de dissolução de fenofibrato - Google Patents

formulações de pastilha e cápsula com taxas melhoradas de dissolução de fenofibrato

Info

Publication number
BR112014014131A2
BR112014014131A2 BR112014014131A BR112014014131A BR112014014131A2 BR 112014014131 A2 BR112014014131 A2 BR 112014014131A2 BR 112014014131 A BR112014014131 A BR 112014014131A BR 112014014131 A BR112014014131 A BR 112014014131A BR 112014014131 A2 BR112014014131 A2 BR 112014014131A2
Authority
BR
Brazil
Prior art keywords
tablet
capsule formulations
dissolution rates
improved
fenofibrate dissolution
Prior art date
Application number
BR112014014131A
Other languages
English (en)
Other versions
BR112014014131B1 (pt
Inventor
Li Michael
Original Assignee
Lts Lohmann Therapie Systeme Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lts Lohmann Therapie Systeme Ag filed Critical Lts Lohmann Therapie Systeme Ag
Publication of BR112014014131A2 publication Critical patent/BR112014014131A2/pt
Publication of BR112014014131B1 publication Critical patent/BR112014014131B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

resumo patente de invenção: "formulações de pastilha e cápsula com taxas melhoradas de dissolução de fenofibrato". a presente invenção refere-se ao desenvolver novas formulações de pastilha e de cápsula usando fenofibrato que é difícil de dissolver e controlar a sua taxa de liberação in vitro.
BR112014014131-2A 2011-12-14 2012-12-14 formulações de pastilha e cápsula com taxas melhoradas de dissolução de fenofibrato e processos para produzir as mesmas BR112014014131B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161570381P 2011-12-14 2011-12-14
US61/570,381 2011-12-14
PCT/IB2012/003123 WO2013114153A2 (en) 2011-12-14 2012-12-14 Wafer and capsule formulations with enhanced dissolution rates for fenofibrate

Publications (2)

Publication Number Publication Date
BR112014014131A2 true BR112014014131A2 (pt) 2017-06-13
BR112014014131B1 BR112014014131B1 (pt) 2021-02-23

Family

ID=48790490

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014014131-2A BR112014014131B1 (pt) 2011-12-14 2012-12-14 formulações de pastilha e cápsula com taxas melhoradas de dissolução de fenofibrato e processos para produzir as mesmas

Country Status (8)

Country Link
US (2) US9849184B2 (pt)
EP (1) EP2790680B1 (pt)
JP (3) JP6149865B2 (pt)
CN (2) CN103987383A (pt)
BR (1) BR112014014131B1 (pt)
CA (1) CA2857430C (pt)
ES (1) ES2717470T3 (pt)
WO (1) WO2013114153A2 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7365409B2 (ja) 2018-06-28 2023-10-19 エイアールエックス エルエルシー 溶解性単位用量膜構造物を製造するための分配方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5785976A (en) * 1993-03-05 1998-07-28 Pharmacia & Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
US5362496A (en) 1993-08-04 1994-11-08 Pharmetrix Corporation Method and therapeutic system for smoking cessation
US6096337A (en) 1996-06-10 2000-08-01 Spireas; Spiridon Liquisolid systems and methods of preparing same
DE19646392A1 (de) 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
IL148685A0 (en) * 1999-09-21 2002-09-12 Rtp Pharma Inc Surface modified particulate compositions of biologically active substances
JP4969761B2 (ja) * 2000-08-31 2012-07-04 オバン・エナジー・リミテッド 所望粒度を持つ固体基材の小粒子および第一材料の小粒状物を含む相乗作用性混合物を製造する方法
WO2003013607A1 (en) * 2001-08-07 2003-02-20 Galephar M/F ORAL PHARMACEUTICAL COMPOSITION CONTAINING A COMBINATION OF FENOFIBRATE AND A HMG-CoA REDUCTASE INHIBITOR
DE10207394B4 (de) 2002-02-21 2007-03-29 Lts Lohmann Therapie-Systeme Ag Geschmacksmaskierte oblatenförmige Arzneizubereitung
EP1680091B1 (en) * 2003-10-10 2017-05-31 Veloxis Pharmaceuticals A/S A solid dosage form comprising a fibrate
KR20060085682A (ko) * 2003-10-10 2006-07-27 라이프사이클 파마 에이/에스 피브레이트 및 스타틴을 함유하는 고형 제제
US20050096390A1 (en) 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and pravastatin
US20070014846A1 (en) * 2003-10-10 2007-01-18 Lifecycle Pharma A/S Pharmaceutical compositions comprising fenofibrate and atorvastatin
CA2601372A1 (en) * 2005-03-30 2006-10-12 Teva Pharmaceutical Industries Ltd. Improved formulations of fenofibrate containing menthol or peg/poloxamer
JP5300477B2 (ja) * 2006-08-01 2013-09-25 大塚製薬株式会社 薬理活性物質の吸収性が改善された医薬組成物
US8623401B2 (en) 2008-03-27 2014-01-07 Fenwafe Inc. Wafer formulation
GB2462022B (en) * 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
MX2011006307A (es) 2008-12-15 2011-10-14 Banner Pharmacaps Inc Metodos para aumentar la liberacion y absorcion de agentes activos insolubles en agua.

Also Published As

Publication number Publication date
JP2017122099A (ja) 2017-07-13
CA2857430A1 (en) 2013-08-08
US20180092979A1 (en) 2018-04-05
WO2013114153A2 (en) 2013-08-08
JP2017114885A (ja) 2017-06-29
WO2013114153A3 (en) 2013-10-31
US20140377342A1 (en) 2014-12-25
US9849184B2 (en) 2017-12-26
JP2015500330A (ja) 2015-01-05
CN103987383A (zh) 2014-08-13
ES2717470T3 (es) 2019-06-21
EP2790680B1 (en) 2018-12-12
US11497811B2 (en) 2022-11-15
JP6149865B2 (ja) 2017-06-21
JP6391730B2 (ja) 2018-09-19
JP6391731B2 (ja) 2018-09-19
EP2790680A2 (en) 2014-10-22
BR112014014131B1 (pt) 2021-02-23
CA2857430C (en) 2019-12-03
CN110496108A (zh) 2019-11-26

Similar Documents

Publication Publication Date Title
TWD161002S (zh) 座標輸入器
BR112015024910A2 (pt) dispositivo de exibição montado na cabeça, método de controle de dispositivo de exibição montado na cabeça e sistema de exibição
MX2020003096A (es) Formulaciones farmaceuticas de un inhibidor de hidroxilasa de hif.
PH12014501910A1 (en) Tamper resistant immediate release formulations
TWD160104S (zh) 展示架之部分
TWD163948S (zh) 顯示面板的圖形化使用者介面之部分
TWD164759S (zh) 可攜式顯示裝置
FR2994364B3 (fr) Dispositif d'affichage affichant une pluralite de vues de contenu, dispositif de lunettes se synchronisant avec l'une des vues de contenu, et procedes connexes
IN2014DN10260A (pt)
TWD158984S (zh) 座標輸入器
TWD158983S (zh) 座標輸入器之部分
BR112014001543A2 (pt) preparação de liberação sustentada de ivabradina ou seus sais farmaceuticamente aceitáveis
IN2015DN03921A (pt)
TR201010683A1 (tr) Vildagliptin formülasyonları.
PE20151543A1 (es) Composicion farmaceutica oral de sales sulfato para comprimidos de uso dual y metodos para su uso
MX2016006087A (es) Formulaciones de desintegracion rapida y metodos de uso.
BR112014014131A2 (pt) formulações de pastilha e cápsula com taxas melhoradas de dissolução de fenofibrato
IN2015DN03929A (pt)
BR112014000836A2 (pt) páginas definidas por usuário para aeronave
TWD164910S (zh) 織物
EA201590732A1 (ru) Диспергируемая таблетка
MX2015008757A (es) Formulaciones de lorazepam de liberacion controlada.
BR112015020773A2 (pt) composição farmacêutica de liberação temporizada
CN302568472S (zh) 鼓形表
QIU et al. Study on the Infrastructure for Spatial Information in Germany

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/12/2012, OBSERVADAS AS CONDICOES LEGAIS.